Unlock stock picks and a broker-level newsfeed that powers Wall Street.

High Growth Tech Stocks To Watch In The US Market

In This Article:

Over the last 7 days, the United States market has remained flat, yet it is up 7.2% over the past year with earnings projected to grow by 14% annually in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive economic trends.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.40%

34.10%

★★★★★★

Arcutis Biotherapeutics

26.42%

58.25%

★★★★★★

Ardelyx

20.63%

59.87%

★★★★★★

Travere Therapeutics

28.83%

64.80%

★★★★★★

TG Therapeutics

25.99%

38.42%

★★★★★★

Alnylam Pharmaceuticals

23.67%

61.11%

★★★★★★

AVITA Medical

27.81%

55.17%

★★★★★★

Alkami Technology

22.46%

76.67%

★★★★★★

Ascendis Pharma

35.16%

60.26%

★★★★★★

Lumentum Holdings

21.34%

120.49%

★★★★★★

Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Organogenesis Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of approximately $674.86 million.

Operations: The company generates revenue primarily from its regenerative medicine segment, amounting to $482.04 million.

Organogenesis Holdings has demonstrated a notable uptick in financial performance, with a significant jump in quarterly sales from $99.65 million to $126.66 million and a swing from a net loss to a net income of $7.67 million. This growth is underscored by their recent inclusion in the S&P Biotechnology Select Industry Index, signaling increased market recognition. Despite challenges in maintaining profitability, with earnings expected to grow by 73.29% annually, the company's strategic focus on R&D might bolster its competitive edge; however, it’s worth noting that their revenue growth rate of 8.6% per year slightly outpaces the broader US market's 8.4%. Looking ahead into 2025, Organogenesis anticipates revenues between $480 million and $535 million, suggesting confidence in sustained growth despite past volatility in earnings and share price movements.

NasdaqCM:ORGO Earnings and Revenue Growth as at May 2025
NasdaqCM:ORGO Earnings and Revenue Growth as at May 2025

TeraWulf

Simply Wall St Growth Rating: ★★★★★☆

Overview: TeraWulf Inc., along with its subsidiaries, functions as a digital asset technology company in the United States and has a market cap of approximately $1.15 billion.